Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1 1

Status

Recruiting 2

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Burkitt Lymphoma 19Lymphoma, Large B-Cell, Diffuse 17Multiple Myeloma 15Lymphoma, Non-Hodgkin 13Lymphoma, Follicular 11Lymphoma 11Leukemia, Myeloid, Acute 11Recurrence 10Ovarian Neoplasms 9Lymphoma, B-Cell 9Myelodysplastic Syndromes 8Pancreatic Neoplasms 7Leukemia, Lymphocytic, Chronic, B-Cell 7Leukemia 7Lymphoma, Mantle-Cell 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Hodgkin Disease 6Hematologic Neoplasms 6Breast Neoplasms 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasms 5Leukemia, Myelomonocytic, Chronic 5Triple Negative Breast Neoplasms 4Stomach Neoplasms 4Sarcoma, Ewing 4Sarcoma 4Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Osteosarcoma 4Lymphoma, Large-Cell, Anaplastic 4

Interventions

Etoposide 3daratumumab 2Vincristine 2Prednisone 2Doxorubicin 2Cyclophosphamide 2prednylidene 1pomalidomide 1deltacortene 1carmustine, poliferprosan 20 drug combination 1Rituximab 1Peripheral Blood Stem Cell Transplantation 1Melphalan 1Dexamethasone 1Cytarabine 1Carmustine 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Plasmablastic Lymphoma × Cyclophosphamide × 30 days × Clear all
NCT04139304 2026-06-01

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

AIDS Malignancy Consortium

Phase EARLY_PHASE1 Recruiting
15 enrolled
Lymphoid

Plasmablastic Lymphoma

NCT05389423 2026-06-01

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
25 enrolled
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡